Cargando…
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
BACKGROUND: Anti(α)-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte tr...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204804/ https://www.ncbi.nlm.nih.gov/pubmed/32303618 http://dx.doi.org/10.1136/jitc-2019-000493 |